Cargando…
In Silico Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes
Background: Second-generation long-acting insulin glargine 300 U/mL (Gla-300) and degludec 100 U/mL (Deg-100) provide novel basal insulin therapies for the treatment of type 1 diabetes (T1D). Both offer a flatter pharmacokinetic (PK) profile than the previous generation of long-acting insulins, thus...
Autores principales: | Schiavon, Michele, Visentin, Roberto, Giegerich, Clemens, Sieber, Jochen, Dalla Man, Chiara, Cobelli, Claudio, Klabunde, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407002/ https://www.ncbi.nlm.nih.gov/pubmed/32125178 http://dx.doi.org/10.1089/dia.2020.0027 |
Ejemplares similares
-
Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial
por: Bolli, Geremia B., et al.
Publicado: (2021) -
Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
por: Buscemi, Silvio, et al.
Publicado: (2019) -
Response to insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
por: Yamabe, Mizuho
Publicado: (2019) -
Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
por: Miller, Michelle, et al.
Publicado: (2021) -
Nocturnal Glycemic Control with New Insulin Glargine 300 U/mL
por: Yu, Neng Chun
Publicado: (2019)